40856-79-9

Usage

Uses

Used in Pharmaceutical Industry:
(5S)-5-(4-hydroxybenzyl)imidazolidine-2,4-dione is used as a pharmaceutical compound for its potential antioxidant and free radical scavenging properties. Its unique structure and potential biological activity make it a candidate for the development of new drugs and therapies.
Used in Organic Synthesis:
In the field of organic synthesis, (5S)-5-(4-hydroxybenzyl)imidazolidine-2,4-dione serves as a key intermediate or building block for the creation of more complex molecules. Its unique structure allows for further chemical modifications and the synthesis of novel compounds with various applications.
Used in Medicinal Chemistry:
(5S)-5-(4-hydroxybenzyl)imidazolidine-2,4-dione is used as a compound in medicinal chemistry for the design and development of new drugs. Its potential biological activity and unique structure make it a valuable tool in the search for new therapeutic agents and treatments for various diseases and conditions.

Upstream product

• 80171-33-1 5-(p-hydroxybenzylidene)hydantoin 
• 590-28-3 potassium cyanate 
• 556-02-5 ?Tyr 
• 54896-65-0 N-carbamoyltyrosine 
• 57-13-6 urea 
• 123-08-0 4-hydroxy-benzaldehyde 
• 6318-40-7 (5Z)-5-(4-hydroxybenzylidene)-2-thioxoimidazolidin-4-one 
• 16652-64-5 O-benzyl-S-tyrosine 
• 60-18-4 L-tyrosine 
• 80171-33-1 5-(4-hydroxybenzylidene)imidazolidine-2,4-dione 

Downstream Products

• 90899-85-7 N-carbamoyl-L-tyrosine 
• 54896-58-1 N-carbamyl-D-tyrosine 
• 54896-65-0 N-carbamoyltyrosine 

Relevant academic research and scientific papers

Discovery of novel 2,5-dioxoimidazolidine-based P2X7 receptor antagonists as constrained analogues of KN62

Novel 2,5-dioxoimidazolidine-based conformationally constrained analogues of KN62 (1) were developed as P2X7 receptor (P2X7R) antagonists using a rigidification strategy of the tyrosine backbone of 1. SAR analysis of the 2,5-dioxoimidazolidine scaffold indicated that piperidine substitution at the N3 position and no substitution at N1 position were preferable. Further optimization of the substituents at the piperidine nitrogen and the spacer around the skeleton resulted in several superior antagonists to 1, including 1-adamantanecarbonyl analogue 21i (IC50 = 23 nM in ethidium uptake assay; IC50 = 14 nM in IL-1β ELISA assay) and (3-CF3-4-Cl)benzoyl analogue (-)-21w (54 nM in ethidium uptake assay; 9 nM in IL-1β ELISA assay), which was more potent than the corresponding (+) isomer. Compound 21w displayed potent inhibitory activity in an ex vivo model of LTP-induced pain signaling in the spinal cord and significant anti-inflammatory activity in in vivo models of carrageenan-induced paw edema and type II collagen-induced joint arthritis.

Synthesis, crystal structure, hydrogen bond patterns and Hirshfeld surface analysis of (S)-5-(4-hydroxybenzyl)-imidazolidine-2,4?dione

The title compound, (S)-5-(4-hydroxybenzyl)-imidazolidine-2,4?dione, a new α-amino acid hydantoin derivative with formula C10H10N2O3 has been synthesized and structurally characterized by MS, FT-IR, NMR, and X-ray diffraction techniques. Spectroscopy results are consistent with the skeleton structure. The powder X-ray diffraction data confirms the phase purity of the crystalline sample. Single-crystal X-ray diffraction analysis indicated that crystallizes in the orthorhombic space group P212121 (N°19), Z = 4, and unit cell parameters a = 6.217(3) ?, b = 7.653(3) ?, c = 19.824(8) ?. The molecular structure and crystal packing are stabilized by intermolecular N–H···O and O–H···O hydrogen formed infinite two-dimensional chains, with graph-set C(6), C(5) and C(11) that run along the a, b and c directions forming a two-dimensional network. Hirshfeld surface analysis confirm that the most important contributions for the crystal packing are from N–H··O and O–H··O interactions. Energy framework calculations suggest that the contacts formed between molecules are slightly electrostatic and revealed that interactions exhibit approximately complex zig-zag shape topology in the crystal structure.

Method for preparing 5-substituted chiral hydantoin

The invention discloses a method for directly preparing a 5-substituted chiral hydantoin compound by asymmetric catalyzing and hydrogenating of hydantoin-derived exocycloolefin. A chemical structural formula of the 5-substituted chiral hydantoin compound is expressed by a formula (I) shown in the description. A chemical reaction equation is shown in the description, wherein a compound (II) is the hydantoin-derived exocycloolefin; a compound (III) is a catalyst, and the catalyst is a metal compound of chiral diphosphine ligand. Compared with the prior art, the method has the characteristics that the chiral multiplication is realized, the efficiency and selectivity are high, the atom economy is realized, the green and non-pollution effects are realized, the industrialization is easy, and the like.